Business
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram
About this update from Korro Bio, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 11:15 a.m. PT (2:15 p.m. ET) in the Borgia Room at The Westin St. Francis Hotel in San Francisco. Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will also be participating at the conference. Dr. Aiyar will present new platform data and preclinical data on its first development candidate, KRRO-110, for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). As previously announced, preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024. A live webcast of the presentation can be accessed from the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days. About Korro Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Mass. For more information, visit korrobio.com. Forward-Looking Statements Certain statements contained in this press release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including express or implied statements regarding the timing of Korro’s regulatory filings for KRRO-110, Korro’s ability to replicate results from preclinical studies in clinical trials, KRRO-110’s ability to...